Assessment of Polypharmacy Prescriptions of Patients With Chronic Kidney Disease for Drug-Drug Interactions

Kidney function gradually declines with chronic kidney disease (CKD). Because diabetes mellitus and hypertension are more common, More people are being diagnosed with chronic kidney disease (CKD) with time. Research shows that polypharmacy is very prevalent in patients with chronic kidney disease (CKD), with prevalence rates frequently above 80%. A cross-sectional study was conducted on 348 subjects receiving polypharmacy prescription for Chronic Kidney Disease. Data were collected from Nephrology Department, Government Medical College Hospital, Kozhikode in the duration of 3 months. The electronic DDI checking platform UpToDate was used to evaluate patient medication regimens. This software identifies and classify DDIs into five types according to the degree of clinical significance. Type A: No known interaction, Type B: No action needed, Type C: Monitor therapy. Type D: Consider therapy modification, and Type X: Avoid combination. Among 348 patients enrolled into the study 333 prescriptions showed drug interaction and 15 prescriptions did not show any interaction. In these 348 prescriptions, 2268 DDIs were identified. 524 interacting pairs were identified, out of which 91 were mild, 365 were moderate, 53 were major and 14 were contraindicated DDIs.